IMR Press / FBL / Volume 11 / Issue 2 / DOI: 10.2741/1880

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Phase II study of neoadjuvant concurrent chemioradiotherapy with oxaliplatin-containing regimen in locally advanced rectal cancer
Show Less
1 Med. Onc Clin Mediterranea, Naples, Italy
2 Radioth Clin Mediterranea Naples, Italy
3 Surgery Clin. Mediterranea Naples, Italy
4 Emergency Surgery S.Giovanni Bosco Hosp Naples, Italy
5 Radioth Ascalesi Hosp Naples, Italy
6 Medical Oncology B INT Pascale Naples, Italy

Academic Editor: Antonio Giordano

Front. Biosci. (Landmark Ed) 2006, 11(2), 1275–1279; https://doi.org/10.2741/1880
Published: 1 May 2006
(This article belongs to the Special Issue Gene targets for modulating cell growth)
Abstract

The purpose of this phase II trial was to assess tolerance and efficacy of the combination of radiation, fluorouracil and oxaliplatin as neoadjuvant treatment in locally advanced rectal cancer. Between March 2001 and August 2004 , 28 patients M/18 F/10 with locally advanced rectal cancer were entered in our study. All the patients underwent to the Radiotherapy with a total dose was 45 Gy and concurrent chemotherapy with Oxaliplatin 80 mg/mq G1 on weeks 1,3,5 followed by five day continuous infusion of 5-Fluorouracile 300 mg/mq on five consecutive weeks. Surgery was planned 5 weeks later. Surgery was performed in all patients after a mean interval time of 5 weeks. Side effects and toxicity included grade II sec WHO diarrhea and grade II mucositis , grade I-II dysuria and skin reaction Downstaging to T0-2N0 was achieved in 18 patients (65%) with 4 (15%) achieving a pathologically complete response.

Conclusions: Such a combined preoperative chemioradiotherapy and oxaliplatin-containing regimen is well tolerated with non increase in surgical toxicity. The good response rate observed warrants its use in further clinical trials.

Keywords
Oxaliplatin
Neoadjuvant
radiochemotherapy
Adenocarcinoma
Cancer
Neoplasm
Tumor
Rectum
Treatment
Therapeutics
Share
Back to top